[go: up one dir, main page]

MX2023010429A - Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). - Google Patents

Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).

Info

Publication number
MX2023010429A
MX2023010429A MX2023010429A MX2023010429A MX2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A MX 2023010429 A MX2023010429 A MX 2023010429A
Authority
MX
Mexico
Prior art keywords
kras inhibitors
kras
inhibitors
compounds
methods
Prior art date
Application number
MX2023010429A
Other languages
English (en)
Inventor
Khehyong Ngu
Upender Velaparthi
Hasibur Rahaman
Brian Edward Fink
Robert Joseph Cherney
Wayne David Vaccaro
Zheming Ruan
Lan-Ying Qin
Pravin S Shirude
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023010429A publication Critical patent/MX2023010429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a inhibidores de KRAS. También se proporcionan métodos de tratamiento de cánceres usando los compuestos.
MX2023010429A 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). MX2023010429A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160436P 2021-03-12 2021-03-12
US202163288965P 2021-12-13 2021-12-13
PCT/US2022/020230 WO2022192790A1 (en) 2021-03-12 2022-03-14 Kras inhibitors

Publications (1)

Publication Number Publication Date
MX2023010429A true MX2023010429A (es) 2023-09-12

Family

ID=81074021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010429A MX2023010429A (es) 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).

Country Status (11)

Country Link
US (1) US20240217982A1 (es)
EP (1) EP4305037B1 (es)
JP (1) JP2024510207A (es)
KR (1) KR20230169968A (es)
AU (1) AU2022232460A1 (es)
BR (1) BR112023017661A2 (es)
CA (1) CA3210383A1 (es)
ES (1) ES3014892T3 (es)
IL (1) IL305572A (es)
MX (1) MX2023010429A (es)
WO (1) WO2022192790A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
IL314812A (en) 2022-02-09 2024-10-01 Quanta Therapeutics Inc Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
EP4499233A1 (en) * 2022-03-25 2025-02-05 Eli Lilly and Company Kras inhibitors
EP4532494A1 (en) 2022-05-25 2025-04-09 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
JP2025536369A (ja) 2022-10-21 2025-11-05 リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US10822312B2 (en) * 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10745385B2 (en) * 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
CA3207854A1 (en) * 2021-02-09 2022-08-18 Liansheng Li Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
IL305572A (en) 2023-10-01
CA3210383A1 (en) 2022-09-15
KR20230169968A (ko) 2023-12-18
US20240217982A1 (en) 2024-07-04
JP2024510207A (ja) 2024-03-06
ES3014892T3 (en) 2025-04-28
BR112023017661A2 (pt) 2023-12-05
WO2022192790A1 (en) 2022-09-15
EP4305037A1 (en) 2024-01-17
AU2022232460A1 (en) 2023-09-14
EP4305037B1 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2025001648A (es) Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras)
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
MX2025013504A (es) Inhibidores de kras de anillo fundido para el tratamiento de enfermedades
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2023008193A (es) Procedimientos para tratar el cáncer.
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2022005726A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
PH12021553000A1 (en) Multispecific proteins
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
MX2023013912A (es) Metodos para inhibir ras.
PH12021552147A1 (en) Rad51 inhibitors
MX2018003351A (es) Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2024013215A (es) Compuestos para inhibir kif18a
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer